Abstract
Cancer Immunotherapy In article number 2205044, Baorui Liu, Rutian Li, and co-workers constructed gelatinase-responsive NanoSwitch to control the activation process of CAR-T cells, leading to on-site activation of CAR-T cells at the tumor region in a sustainable way. This platform has promising potential to prevent the main obstacles in the CAR-T therapy for solid tumors including cytokine-release syndrome and on-target/off-tumor toxicity.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
